Sequana Medical announces 2021 Full Year Results and 2022 Outlook
April 12, 2022 01:00 ET
|
Sequana Medical
alfapump® in liver disease Positive results from second interim analysis of POSEIDON pivotal study; encouraging survival data at 12 months vs. published literaturePatient enrolment and implants...
Sequana Medical to present at Needham’s Healthcare Conference and attend Kempen’s Life Sciences Conference in April 2022
April 08, 2022 01:00 ET
|
Sequana Medical
GHENT, Belgium, April 08, 2022 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), an innovator in the treatment of diuretic-resistant fluid...
Sequana Medical Announces the Completion of alfapump Implantations in POSEIDON, the North American Pivotal alfapump Study
April 05, 2022 01:00 ET
|
Sequana Medical
Reporting of primary endpoint on track for Q4 2022FDA regulatory submission on track for mid-202370% survival of POSEIDON Roll-In patients at one year post-implantation1 compares favourably to...
Sequana Medical Notice of 2021 Full Year Results and Business Update
March 31, 2022 01:00 ET
|
Sequana Medical
GHENT, Belgium, March 31, 2022 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), an innovator in the treatment of diuretic-resistant fluid...
Transparency Notifications from Shareholders
March 28, 2022 13:00 ET
|
Sequana Medical
GHENT, Belgium, March 28, 2022 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), an innovator in the treatment of diuretic-resistant fluid...
Transparency Notifications from Shareholders
March 18, 2022 13:00 ET
|
Sequana Medical
GHENT, Belgium, March 18, 2022 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), an innovator in the treatment of diuretic-resistant fluid...
Sequana Medical Announces New Share Capital Amount and New Number of Shares
March 10, 2022 12:00 ET
|
Sequana Medical
GHENT, Belgium, March 10, 2022 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), an innovator in the treatment of diuretic-resistant fluid...
Sequana Medical to Present at BioCapital Europe and Oppenheimer’s Annual Healthcare Conference
March 09, 2022 01:00 ET
|
Sequana Medical
GHENT, Belgium, March 09, 2022 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid...
Sequana Medical Receives Certification Under MDR, the New European Medical Device Regulation
February 14, 2022 01:00 ET
|
Sequana Medical
alfapump® is one of the first novel Class III active implantable medical devices to be certified GHENT, Belgium, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA, the...
Sequana Medical to present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
February 03, 2022 01:00 ET
|
Sequana Medical
GHENT, Belgium, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid...